Gilead Sciences stock heads into the open after a 0.9% gain
Published on 09/17/2026 at 06:01 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Gilead Sciences stock closed at USD 147.68 on the Nasdaq on September 16, 2026, gaining 0.94% from the prior close of USD 146.30. The shares traded between a day low of about USD 146.20 and a high near USD 149.30, with the move outpacing a marginal 0.01% decline in the Nasdaq composite over the same session.
September 16, 2026 in numbers
Gilead Sciences Inc. (ISIN US3755581036, Nasdaq: GILD) ended the September 16, 2026 session at USD 147.68 on the Nasdaq, up 0.94% versus the prior close at USD 146.30. Per Nasdaq data cited on a global investment platform, the stock's intraday range ran roughly from USD 146.20 on the downside to around USD 149.30 at the top on the same date, indicating moderate volatility within the established 52-week corridor.INDmoney The closing gain contrasted with the broader backdrop, as the Nasdaq composite slipped 3.15 points, or 0.01%, to 25,978.42 on September 16, 2026, while the S&P 500 fell 0.44% and the Dow Jones Industrial Average lost 1.21% over the session.Las Vegas Sun In parallel, an overseas market wrap also reported Gilead Sciences at USD 147.68, up USD 1.38 or 0.94%, reinforcing the picture of modest outperformance against a weak blue-chip backdrop for that date.Ameblo
Beyond the numbers, the September 16, 2026 move in Gilead Sciences aligned with a series of announcements around its HIV prevention portfolio. The company said it had expanded six royalty-free voluntary licensing agreements to include its investigational once-yearly lenacapavir for HIV prevention across 120 countries, highlighting efforts to broaden access in low- and middle-income regions.Investing.com In a related development, Gilead announced an agreement with the Pan American Health Organization to accelerate access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean, creating a regional pathway that complements its licensing programs.Zacks Commentary from an equity-research portal underscored that these access and licensing moves expand Gilead's HIV prevention reach beyond its existing voluntary licensing framework, adding a policy and public-health dimension that investors weighed alongside the stock's valuation metrics.Simply Wall St
Today’s focus for Gilead Sciences
Heading into today, September 17, 2026, Gilead Sciences carries the previous Nasdaq close of USD 147.68 and a modest outperformance versus the Nasdaq composite from the last session, setting the stage for trading ahead of the opening bell. Recent coverage has highlighted that the stock is trading at a price-to-sales ratio above its historical median and appears materially overvalued relative to certain intrinsic value estimates, an angle that may continue to shape sentiment as investors digest the latest HIV prevention access updates.GuruFocus At the same time, the broader macro backdrop remains sensitive to monetary-policy expectations after the recent session saw major US stock indexes decline on rate and tightening signals, a context that can influence risk appetite toward large biopharmaceutical names like Gilead Sciences.Ajou Economic Daily No specific company-scheduled earnings release or annual meeting falls on September 17, 2026 in the visible calendars, so attention today centers on how the market continues to price Gilead's HIV prevention partnerships and valuation profile against the evolving macro environment.
